Not a good buy right now for an impatient buyer: the stock is still in a bearish longer-term trend (SMA_200 > SMA_20 > SMA_5) and is heading into earnings (2026-02-05 after hours) with elevated implied volatility.
Near-term momentum has improved (MACD turning positive; RSI neutral-to-bullish), but trend confirmation is lacking; risk/reward is not attractive before the earnings event.
Price: 96.92 (+2.68%) while S&P 500 is down (-0.37%) → relative strength today.
Momentum: MACD histogram +0.077 and expanding → bullish momentum building.
RSI(6): 59.5 → neutral (not overbought), room for upside but not a strong trigger alone.
Trend/structure: bearish moving-average stack (SMA_200 > SMA_20 > SMA_5) → broader trend still bearish; rallies may face supply.
Key levels: Pivot 96.419 (price slightly above).
Resistance: 99.341 (R1), 101.147 (R2).
Support: 93.497 (S1), 91.691 (S2).
Pattern-based odds: similar-pattern projection suggests modest drift up (next month +4.76% probability bias), but it’s not strong enough to override the earnings/event risk.
Options Data
Bearish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Sentiment (open interest): Put/Call OI ratio = 2.84 (puts 981 vs calls 346) → positioning skews defensive/bearish (or hedged) into the event.
Sentiment (today’s volume): Put volume is 0 vs call volume 1422 → today’s flow is call-only, but may be short-dated/speculative ahead of earnings.
Volatility: 30D IV 38.52 vs historical vol 18.7; IV percentile 86.85 → options are priced expensive, consistent with earnings risk.
Activity: today’s volume vs 30D average = 2370% → unusually high attention/positioning right before earnings.
Technical Summary
Sell
7
Buy
5
Positive Catalysts
Business execution trend: last reported quarter showed strong YoY growth (revenue, net income, EPS).
Neutral/Negative Catalysts
suggests meaningful hedging or bearish positioning into the print.
No supportive “strong buy” timing help from Intellectia signals (no AI Stock Picker or SwingMax trigger).
Gross margin: 90.05, +0.38% YoY → modest margin improvement; overall trend supportive going into the next report.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating or price-target change data was provided in the dataset, so a verified recent trend cannot be summarized here.
Wall Street-style pros (based on provided fundamentals): consistent YoY revenue growth and faster earnings/net income growth.
Wall Street-style cons (based on provided market/positioning): pre-earnings uncertainty with elevated IV and put-heavy open interest; technical trend still not fully repaired.
Influential/political activity check: insiders and hedge funds are described as neutral; no recent congress trading data available.
Wall Street analysts forecast EHC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EHC is 143.33 USD with a low forecast of 140 USD and a high forecast of 150 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast EHC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EHC is 143.33 USD with a low forecast of 140 USD and a high forecast of 150 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 99.560
Low
140
Averages
143.33
High
150
Current: 99.560
Low
140
Averages
143.33
High
150
Barclays
NULL -> Overweight
maintain
$150 -> $153
AI Analysis
2026-02-06
New
Reason
Barclays
Price Target
$150 -> $153
AI Analysis
2026-02-06
New
maintain
NULL -> Overweight
Reason
Barclays raised the firm's price target on Encompass Health to $153 from $150 and keeps an Overweight rating on the shares. The firm updated the company's model post the Q4 report.
Barclays
Andrew Mok
Overweight
maintain
$141 -> $150
2025-10-30
Reason
Barclays
Andrew Mok
Price Target
$141 -> $150
2025-10-30
maintain
Overweight
Reason
Barclays analyst Andrew Mok raised the firm's price target on Encompass Health to $150 from $141 and keeps an Overweight rating on the shares. The company reported a modest Q4 beat, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for EHC
